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Monocyte chemoattractant protein-1 mediates collagen depo- clinical importance [2, 3]. Chemokines are peptide mole-
sition in experimental glomerulonephritis by transforming cules and are classified according to their amino acid
growth factor-b. sequence, and are divided into two large groups:Background. Monocyte chemoattractant protein-1 (MCP-1)
a- and b-chemokines [3]. Among the b-chemokines,plays a significant role in the recruitment of monocytes/macro-
monocyte chemoattractant protein-1 (MCP-1) exertsphages in experimental glomerulonephritis (GN). Because re-
cent evidence points to possible profibrogenic effects of leuko- strong chemoattractant activity to monocytes/macro-
cyte-derived factors in GN, this study was designed to evaluate phages (M/M) and lymphocytes [4, 5]. Recent studies
the role of the chemokine MCP-1 in the fibrogenesis of experi- that applied chemokine-neutralizing approaches re-mental GN.
vealed that leukocyte infiltration in glomerulonephritisMethods. Rats with an anti-thy-1–induced GN were treated
(GN) is largely chemokine dependent and that MCP-1with a neutralizing antiserum against MCP-1. Glomerular colla-
gen type IV, as a marker of glomerular matrix deposition, was plays a central role in glomerular monocyte recruitment
assessed by Northern and Western blotting and immunohistol- [6–11].
ogy. Transforming growth factor-b (TGF-b), an important me- Glomerular inflammatory cell infiltration in GN playsdiator of this matrix expansion, was studied by Northern and
an important role in the development of GN and is ac-Western blotting.
companied by the deposition of extracellular matrix.Results. The induction of GN resulted in a significant in-
crease of glomerular collagen type IV deposition and TGF-b There is evidence that the inflammatory cell infiltrate
synthesis. The neutralization of MCP-1 significantly reduced predisposes the development of the fibrotic process in
the enhanced collagen type IV protein synthesis and deposition GN, as leukocyte-derived factors can promote, initiate,
without affecting collagen mRNA expression. However, both
or enhance fibrosis [12]. The inhibition of inflammatorythe enhanced transcription and protein synthesis of TGF-b
cell infiltration might therefore be an important measurewere inhibited by anti–MCP-1 antiserum in nephritic animals.
in the prevention of renal scarring. This study was de-Conclusions. In this model of GN, MCP-1 has a fibrogenic
effect through the stimulation of TGF-b. MCP-1 is thus not signed to evaluate whether the neutralization of MCP-1
only important for the recruitment of inflammatory cells, but influences extracellular matrix deposition in the glomer-
also mediates glomerular matrix accumulation. ulus. Collagen type IV was used as a marker because it
is strongly expressed in the glomerular matrix during the
course of this form of experimental GN (abstract; J Am
Inflammatory cell recruitment into injured tissue is Soc Nephrol 7:1755, 1996) [13].
a coordinated event that involves cell adhesion to the Our experiments show that neutralization of MCP-1
endothelium followed by directed movement of the leu- reduces collagen type IV formation by inhibition of
kocytes [1]. This latter process is regulated by chemoat- transforming growth factor-b (TGF-b). MCP-1 is there-
tractants [1]. Among the various chemoattractants, chemo- fore not only an important mediator of monocyte recruit-
kines have emerged as a family of molecules with great ment, but also has profibrogenic effects.
Key words: monocytes, macrophages, fibrogenesis, inflammation, glo- METHODSmerular matrix.
Generation of anti–monocyte chemoattractant
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The specificity of the antibody and its neutralizing activ- cDNA inserts as described earlier [13]. Membranes were
hybridized with 1 3 106 cpm/probe per milliliter of hy-ity on chemotaxis were described earlier [10].
bridization buffer [5 3 SSPE (43.5 g NaCl, 6.9 g NaH2
Induction of glomerulonephritis and PO4 3 H2O, 1.85 g EDTA/liter, pH 7.4), 2 3 Denhardt’s
experimental design solution 150 mg/ml, sonicated and denatured salmon
sperm DNA (Sigma Chemical Co., St. Louis, MO, USA),Immune-mediated mesangial cell injury was induced
in male Wistar rats (180 to 200 g) by intravenous injection 0.1% sodium dodecyl sulfate (SDS), 5% dextran sulfate,
and 50% formamide] for 18 hours at 428C. The mem-of 0.5 ml/100 g body wt of an antirat thymocyte antiserum
(ATS). ATS was induced in rabbits by repeated immuni- branes were washed twice in 2 3 standard saline citrate
(SSC)-0.5% SDS (20 3 SSC: 3 m sodium chloride-0.3 mzation with thymocytes from Lewis rats, as described
earlier [14]. The following groups of animals were sodium citrate) for 30 minutes at room temperature and
subsequently in 0.4 3 SSC-0.5% SDS at 658C for 30studied.
Controls. Animals intravenously received 0.5 ml/100 minutes. Autoradiography was performed for 2 to 72
hours at 2808C with intensifying screens. Nylon mem-g body wt of nonimmune rabbit serum, which was fol-
lowed by a second intravenous injection of 0.3 ml nonim- branes were stripped for 60 minutes in 5 mm Tris-HCl
(pH 8.0), 0.5% sodium pyrophosphate, 5 3 Denhardt’s,mune rabbit serum five minutes after the first intravenous
application. and 0.2 mm ethylenediaminetetraacetic acid (EDTA; pH
8.0) at 658C and were rehybridized with a 0.58 kb EcoRINephritis. Animals intravenously received 0.5 ml/100
g body wt of ATS. Five minutes following antiserum, cDNA probe of human 18 S RNA to account for small
loading and transfer variabilities.the rats were injected with 0.3 ml of nonimmune rabbit
serum.
Western blotting for collagen type IV andNephritis plus anti–MCP-1 antiserum. To study the
transforming growth factor-beffects of MCP-1, the animals received 0.3 ml of a rabbit
antirat MCP-1 antiserum five minutes following the in- For Western blotting, glomeruli of four animals of
each group were isolated and centrifuged in 1 3 phos-duction of the GN with ATS.
Nephritis plus anti–TGF-b antiserum. To study the phate-buffered saline (PBS). The pellet was resuspended
in 100 ml of Laemmli buffer (33% v/v 0.5 m Tris-HCl,effect of TGF-b on the deposition of collagen type IV,
animals intravenously received 250 mg of a mouse mono- pH 6.81 66% v/v 10% SDS). Samples were boiled for 10
minutes and were centrifuged. The protein concentrationclonal anti–TGF-b1, -b2, -b3 antibody (Genzyme Diag-
nostics, Cambridge, MA, USA) five minutes following was determined with a modified Lowry method (Protein
DC-assay; Bio-Rad, Hercules, CA, USA). Two equalATS.
Animals of all groups (except the groups that were amounts of protein (50 mg) 1/4 vol% Laemmli buffer 2
(50% b-mercaptoethanol, 50% glycerol) and 1/5 vol%treated with anti–TGF-b) were studied at 24 hours and
5 and 10 days following the induction of the GN. The staining solution (42.5% glycerol, 0.5% xylacyanol, 0.5%
bromphenol blue) were added. The solution was loadedexperiments were carried out in at least two complete
sets, with four animals per group in each set. onto a polyacrylamide SDS-8% gel and electrophoresed.
A low molecular weight marker (Rainbow marker; Am-
Isolation of glomeruli and total RNA for Northern ersham, Braunschweig, Germany) that compromises
blot hybridization 14.3 to 200.0 kD served as a molecular weight standard.
After the completion of electrophoresis, proteins wereGlomeruli were isolated by a fractional sieving tech-
nique as described earlier [15]. The yield and purity of electroblotted semidry (anode buffer I, 30 mm Tris, 20%
methanol; anode buffer II, 300 mm Tris, 20% methanol;glomeruli at each time point were comparable (purity
greater than 90%). Glomeruli were pooled from four cathode buffer, 25 mm Tris, 40 mm 6-aminohexane acid,
20% methanol) for 45 minutes at 0.8 mA/cm2 to a nitro-animals of each group, and cellular RNA was isolated
by the guanidinium isothiocyanate method [16]. RNA cellulose membrane (Hybond ECL; Amersham). The
membrane was blocked in 5% nonfat dry milk in washingwas electrophoresed through a 1.2% agarose gel con-
taining 2.2 m formaldehyde. Equal loading of the lanes buffer (1 3 PBS, 0.1% Tween 20) for one hour at room
temperature and then incubated for another hour withwas evaluated by ethidium bromide staining of the 18
and 28 S RNA. The RNA was transferred to nylon mem- a goat antihuman collagen type IV antibody (Southern
Biotechnology, Birmingham, AL, USA) added to a con-branes (Zetabind, Cuno, Meriden, CT, USA) by vacuum
blotting and ultraviolet cross-linking. Then the mem- centration of 1:500 in the same buffer or a TGF-b anti-
body, respectively. Human natural TGF-b1 (Sigma) andbranes were hybridized with the following probes: a rat
520 bp TGF-b1 EcoRI cDNA fragment and a 1.3 kb recombinant human latent TGF-b1 (R&D Systems,
Wiesbaden, Germany) were used as TGF-b standards.mouse collagen a1 (IV) PSTI cDNA fragment after (32P)
dCTP labeling by random oligonucleotide priming of the After rinsing the membrane in washing buffer for 3 3
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Fig. 1. Glomerular mRNA levels of collagen
type IV (Coll IV) in nephritic animals (nephri-
tis) increased markedly at days 5 and 10 when
compared with controls (C). The neutralizing
anti–monocyte chemoattractant protein-1 (anti–
MCP-1) antiserum had no effect on glomerular
mRNA expression of collagen type IV (nephri-
tis 1 anti–MCP-1).
8 minutes, the secondary antibody, a rabbit antigoat im- Histology
munoglobulin G conjugated to horseradish peroxidase Kidney tissues were either fixed in 1% buffered form-
(Southern Biotechnology) was added at a concentration aldehyde or in Methyl Carnoy’s solution. Tissue sections
of 1:1000. The luminescence detection of peroxidase was (2 mm) were stained with periodic acid-Schiff’s reagent
performed with the ECL system according to the manu- or with the APAAP complex when primary antibodies
facturer’s recommendations (Amersham) after rinsing were used for immunohistology. Tissue was stained with
the following antibodies: a goat antirabbit IgG (Dako-membranes in washing buffer 1 3 PBS. Films were ex-
patts, Hamburg, Germany), a goat antitype IV collagenposed for 5 to 30 minutes at room temperature.
antibody (Biozol, Eching, Germany), and a monoclonal
anti–ED-1 antibody (Chemicon International, Teme-Bioassay for transforming growth factor-b
cula, CA, USA). All quantitative morphological analysesThe inhibition of (3H) thymidine incorporation into
were performed in a blinded fashion. The evaluation ofDNA of CCL-64 mink lung epithelial cells was used
ED-1–positive cells was performed by counting positiveas a sensitive bioassay for TGF-b [17, 18]. We have
cells in at least 80 glomeruli (range 80 to 110) of fourpreviously confirmed the sensitivity and specificity of the
kidneys at each time point as described earlier [20].assay using recombinant TGF-b and TGF-b antibody in
For the evaluation of extracellular collagen deposition,
conditioned media of a proximal tubular cell line [19]. a modified score adopted from Raij, Azar, and Keane
CCL-64 cells were obtained from the American Type [21] and Olson, Wilson, and Heptinstall [22] were ap-
Culture Collection (Rockville, MD, USA) and were plied. At least 80 glomeruli were evaluated in each kid-
seeded at a concentration of 104 cells per well of a 96-well ney section from four animals per time point. The per-
plate in Dulbecco’s modified Eagle’s medium (DMEM) centage of glomerular matrix area stained by antitype
with 10% fetal calf serum (FCS). After 24 hours, the IV collagen antibody was approximated and classified,
medium was changed to serum-free DMEM for another applying a score consisting of grades 0 to 4, with grade
24 hours. CCL-64 cells were then incubated for an addi- 0 representing staining of 0 to 5% of the matrix area,
tional 24 hours with conditioned medium from isolated grade 1 representing staining of 5 to 20%, grade 2 stain-
glomeruli. This medium was obtained by incubating iso- ing 20 to 40%, grade 3 staining of 40 to 60%, grade 4
lated glomeruli of individual animals of the different staining of more than 60%. The calculation of collagen
study groups in defined serum-free DMEM at 378C for deposition index was done in the following manner: The
four hours. Cells were pulsed with (3H) thymidine for number of glomeruli with a score of 1 was multiplied by
the last 12 hours of culture, harvested, and processed as 1. Glomeruli with a score of 2 were multiplied by 2.
Those with a score of 3 were multiplied by 3, and withdescribed earlier [19].
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Fig. 2. Immunohistological staining of renal tissue with a collagen type IV antibody demonstrated positivity in the glomerular mesangium and
the capillary walls in control animals (A and B). Kidney sections of nephritic animals revealed a marked increase of glomerular collagen type IV
deposition five days after induction of the nephritis (C and D). When the animals received the anti–MCP-1 antiserum, the glomerular collagen
deposition was substantially reduced (E and F).
a score of 4 by 4. These numbers were added and divided less than 0.05. To compare two distinct treatment groups,
we applied the Mann–Whitney test. For comparison ofby the number of glomeruli assessed, including those
with a score of 0. all three treatment groups (that is, nephritic/treated/con-
trol), the Kruskal–Wallis ranks test was used. If not indi-
Statistical analysis cated otherwise, the results of the Mann–Whitney test
always correspond to comparison of nephritic versusResults are expressed as means 6 sem unless stated
otherwise. Statistical significance was defined as a P of treated animals.
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Fig. 2. Continued.
Table 1. Effect of monocyte chemoattractant protein-1RESULTS
(MCP-1) neutralization on glomerular collagen
type IV depositionEffect of monocyte chemoattractant protein-1
neutralization on collagen type IV formation Nephritis 1
Controls Nephritis anti-MCP-1When studied by Northern blotting, the expression of
(N 5 4) (N 5 4) (N 5 4)collagen type IV was detectable in glomeruli of control
5 days 1.2260.09 3.09 60.49a 1.8760.27banimals (Fig. 1). The induction of the nephritis markedly
10 days 1.7360.21 2.56 60.34a 1.8260.53b
stimulated glomerular collagen type IV mRNA levels at
The morphologic quantitative assessment of glomerular collagen type IV
days 5 and 10. The neutralizing anti–MCP-1 antiserum shows that neutralization of MCP-1 reduces collagen deposition by up to 40%
at day 5 and day 10 (N 5 animals studied at each time point).had no effect on the mRNA levels of collagen type IV a P , 0.05 vs. controls
at all time points studied (Fig. 1). b P , 0.05 vs. nephritis
Immunohistological staining of renal tissue from con-
trol rats with an antibody against collagen type IV re-
vealed staining in the glomerular mesangium, along the Effect of monocyte chemoattractant protein-1
capillary loops, Bowman’s capsule, and the tubular base- neutralization on transforming growth
ment membranes (Fig. 2 A, B). Immune staining for factor-b formation
collagen type IV increased in nephritic animals at day
The induction of GN resulted in a significant increase5, with very prominent staining in the glomerular intersti-
of TGF-b mRNA expression in glomeruli at 24 hours
tium (Fig. 2 C, D). When the nephritic rats were treated and 5 and 10 days (Fig. 4). This effect was blocked by
with the anti–MCP-1 antiserum, immunohistological the anti–MCP-1 antiserum at all time points (Fig. 4).
staining for collagen type IV in diseased glomeruli was When gel-separated proteins of isolated glomeruli were
substantially reduced (Fig. 2 E, F). incubated with a monoclonal antibody against TGF-b,
The quantitative assessment of the histological changes various proteins were detected (Fig. 5). The amount of
revealed a more than 50% reduction of collagen type protein detectable was markedly enhanced in nephritic
IV deposition in glomeruli at day 5 and a reduction of animals when compared with controls. The strongest
40% at day 10 (Table 1). When studied by Western protein expression was detected at sizes corresponding
blotting, collagen type IV appeared as a double band at to the molecular weight markers of approximately 25
220 kD. Protein was increased in nephritic animals when and 80 kD, less protein corresponding to the marker of
compared with the control animals but returned to al- approximately 12.5 kD (Fig. 5). The signals at these
most control values when the animals were treated with molecular sizes correspond to the TGF-b monomer (12.5
kD), dimer (25 kD), and the latent TGF-b (80 kD).the anti–MCP-1 antiserum (Fig. 3).
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When assessed by densitometry, TGF-b (dimer protein) DISCUSSION
levels were threefold higher at 24 hours, sevenfold higher The glomerular infiltration of monocytes in experi-
at 5 days, and 15-fold higher at 10 days compared with mental GN is partially regulated by MCP-1 [8–10]. Be-
controls. At all time points studied, the in vivo neutraliza- cause infiltrating monocytes are often a prerequisite for
tion of MCP-1 reduced TGF-b (Fig. 5), which reveals tissue sclerosis in diseased kidneys, it is possible that
that MCP-1 neutralization inhibits TGF-b protein syn- cell infiltration might influence scarring. However, it is
thesis. unclear whether or not MCP-1 has fibrogenic effects in
the kidney that are eventually independent of its effect
Monocyte/macrophage infiltration on cell recruitment. We studied collagen type IV as
marker of fibrosis because this protein is a major compo-Twenty-four hours following the initiation of the GN,
nent of the extracellular matrix in the glomerulus of anti-M/M infiltration in nephritic glomeruli was increased
thy-1 nephritis (abstract; ibid) [13].when compared with controls (Table 2). The anti–MCP-1
To evaluate the effect of MCP-1 on collagen typeantiserum reduced M/M infiltration by almost 50% at
IV formation, animals received a MCP-1–neutralizing24 hours. Glomerular M/M appearance in nephritic glo-
antiserum [10]. This approach reduced glomerular mono-meruli decreased over 5 and 10 days. In nephritic rats
cyte infiltration by 50% compared with nephritic controlstreated with anti–MCP-1 antiserum, the glomerular
(Table 2) and confirmed our earlier observations in thisM/M infiltration at day 5 was not significantly different
model [10]. When kidney tissues were assessed by immu-from nephritic rats. Surprisingly, the number of M/M in
nohistology at days 5 and 10 after the induction of nephri-animals receiving the anti–MCP-1 antiserum was higher
tis, glomerular type IV collagen deposition was signifi-
at day 10 when compared with the nephritic animals.
cantly higher in nephritic rats compared with controls.
In animals that had received the anti–MCP-1 antiserum,Effect of transforming growth factor-b antibody on
the deposition of collagen type IV was reduced (Table
collagen type IV deposition 1 and Fig. 2). This effect of the anti–MCP-1 antiserum
A combined in vivo/in vitro approach was applied to was probably not due to transcriptional regulation be-
test whether the increased TGF-b formation in glomeruli cause mRNA levels for collagen type IV were unchanged
of nephritic rats is biologically active and affects collagen (Fig. 1).
type IV deposition. An in vitro assay for TGF-b was An important regulator of extracellular matrix forma-
used to determine its relative amount in supernatants of tion in the anti-thy-1 model of GN is TGF-b [23, 24].
TGF-b stimulates collagen formation by transcriptionalisolated glomeruli of differently treated rats. Because
or nontranscriptional mechanisms [25, 26]. BecauseTGF-b inhibits the growth of CCL-64 mink lung epithe-
TGF-b has this central role in matrix formation in renallial cells, supernatants of isolated glomeruli from control,
disease, the expression of TGF-b following MCP-1 neu-nephritic, and anti–TGF-b treated nephritic rats were
tralization was studied. Western blotting for TGF-b re-tested for their growth effects on CCL-64 cells. The con-
vealed enhanced formation of different sizes of proteinsditioned medium from glomeruli of nephritic animals
in nephritic rats (Fig. 5). This suggests that TGF-b ap-significantly reduced growth of CCL-64 cells, when as-
pears in nephritic glomeruli in different forms. Studiessessed by (3H)-thymidine uptake (Table 3), thereby dem-
in normal glomeruli demonstrate that TGF-b appears asonstrating increased TGF-b formation in nephritic glo-
mature monomer, dimer, or latent molecule [27]. Thesemeruli. This was further supported by examining the
various forms of TGF-b are expressed differently in theeffect of treating nephritic animals with a neutralizing
model we studied. TGF-b is predominantly expressed
antibody to TGF-b. When conditioned media from ne-
as a dimer (approximately 25 kD) and a protein that
phritic animals treated in vivo with a neutralizing TGF-b corresponds to a standard or latent TGF-b (approxi-
antibody were applied in the assay, cell growth almost mately 80 kD). Only small amounts of protein were de-
doubled compared with nephritic rats. This shows that tected that correspond to the TGF-b monomer. Glomer-
TGF-b is responsible for the observed effect and that in ular TGF-b protein levels steadily increased from 24
vivo TGF-b formation could be blocked by treatment hours to 10 days in the nephritic rats, with a maximum
with the anti–TGF-b antibody. at day 10. The treatment of nephritic animals with the
Second, the effect of the treatment with the anti–TGF-b anti–MCP-1 antibody significantly reduced all forms of
antibody on glomerular collagen deposition was assessed TGF-b protein detected in the glomeruli (Fig. 5). It is
by immunohistology. Glomerular collagen type IV stain- unclear how the various isoforms of TGF-b are regulated
ing, which is enhanced in nephritic glomeruli at five days, in the anti-thy-1 GN; however, the induction of proteases
is significantly reduced in nephritic animals treated with might be important [28, 29]. Proteases, such as furin,
could lead to an autoinduction loop of TGF-b formationthe anti–TGF-b antibody (Table 4).
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Fig. 3. By Western blotting, glomerular collagen type IV was detectable as a double band at the size of about 220 kD. In nephritic rats, the
amount of protein was higher compared with the controls. Animals treated with anti–MCP-1 expressed significantly less collagen type IV protein
at days 5 and 10 than untreated nephritic rats.
Fig. 4. The induction of glomerulonephritis (nephritis) stimulated the glomerular mRNA expression of transforming growth factor-b (TGF-b) at
24 hours and 5 and 10 days when compared with control animals (C). The neutralization of MCP-1 (nephritis 1 anti–MCP-1) abolished this
glomerular mRNA stimulation in the nephritic animals at all time points.
by transcriptional and translational events [28–30]. Such ing antiserum to TGF-b in vivo reversed the changes
induced by the nephritis. Treatment with the TGF-b–an amplification loop might be responsible for the in-
creasing amounts of glomerular TGF-b in our experi- neutralizing antiserum also reduced the deposition of
collagen type IV in glomeruli, clearly underlining a rolements.
To assure that the TGF-b that was detected by West- for TGF-b as a mediator of matrix formation in this
disease (Table 4).ern blotting was biologically active and in fact could
mediate collagen type IV synthesis in the nephritis, ani- Inhibition of MCP-1 blocks the formation of TGF-b
mRNA (Fig. 4) and protein expression (Fig. 5), sug-mals were treated with a TGF-b–neutralizing antiserum.
The results of the lung mink cell assay (Table 3) demon- gesting that MCP-1 is a mediator of the increased TGF-b
formation in this injury. The cellular and molecularstrate that glomerular TGF-b from nephritic animals was
biologically active and that treatment with the neutraliz- mechanisms of this effect in the kidney are unclear and
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Fig. 5. By Western blotting, strong positivity for TGF-b1, -b2, -b3 was detectable in nephritic glomeruli (nephritis) when compared with control
animals (C). The proteins detected with the antibody have different molecular sizes that may reflect various forms of TGF-b in glomeruli. A
control gel compromising TGF-b monomer (12.5 kD), dimer (25 kD), and latent form (80 kD) is shown on the right. The protein formation in
nephritic animals increased from 24 hours to 10 days. The neutralizing anti–MCP-1 antibody prevented the increase in TGF-b formation (nephritis 1
anti–MCP-1), detectable in nephritic animals (nephritis).
Table 2. Effect of anti-monocyte chemoattractant protein-1
(MCP-1) antiserum on glomerular monocyte/macrophage
(M/M) infiltration Table 3. Effect of conditioned media from isolated glomeruli on
growth of CCL-64 mink lung epithelial cells, role of transforming
Nephritis 1 growth factor-b (TGF-b) and in vivo treatment with anti-TGF-b
Controls Nephritis anti-MCP-1
(N 5 4) (N 5 4) (N 5 5) Controls Nephritis Nephritis 1 anti-TGF-b
24 hours 0.3760.17 3.27 60.92a 1.9460.67b cpm
5 days 2.0660.65 1.65 60.46
7046145 495698a 9606278b10 days 1.0660.20 1.8560.75b
Conditioned media of isolated glomeruli from nephritic animals at day 5The anti-MCP-1 antiserum reduced M/M recruitment in nephritic glomeruli reduced (3H)-thymidine incorporation in lung epithelial cells (CCL-64) whenat 24 hours, however, had no effect at day 5. At day 10 M/M appearance in compared to controls (aP , 0.001 vs. controls). When nephritic animals wereanimals that received the anti-MCP-1 antiserum was higher compared with ne- treated with an anti-TGF-b antibody in vivo, conditioned media of their isolatedphritic animals (N 5 animals studied at each time point). glomeruli reversed this suppression of cell growth compared to nephritic animalsa P , 0.05 vs. controls (b P , 0.001 vs. nephritis). Glomerular supernatants of at least 8 individualb P , 0.05 vs. nephritis animals were studied per group.
deserve further detailed in vitro studies. Because recent
experiments in lung fibroblasts reveal that MCP-1 can
stimulate TGF-b by transcriptional mechanisms [31], it Table 4. Effect of anti-TGF-b on glomerular collagen
type IV depositionseems possible that MCP-1 might directly affect TGF-b
formation in glomerular cells as well. Additionally, re- Controls Nephritis Nephritis 1 anti-TGF-b
duced TGF-b formation in this nephritis might be due (N 5 4) (N 5 4) (N 5 4)
to a reduction of glomerular monocyte infiltration by 1.2260.09 2.0860.13a 1.5260.006b
neutralization of MCP-1. Monocytes that infiltrate the The quantitative assessment of glomerular collagen type IV deposition re-
vealed that the in vivo treatment with the anti-TGF-b antibody significantlyglomerulus in the anti-thy-1 disease might produce
inhibited glomerular collagen type IV deposition in nephritic animals at 5 days.TGF-b [24]. However, the assessment of glomerular a P , 0.05 vs. controls
b P , 0.05 vs. nephritisM/M infiltration in our experiment reveals that even
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1 mediated glomerular macrophage infiltration in anti-GBM Abthough the number of monocytes decreases in nephritic
GN. Kidney Int 50:665–671, 1996
glomeruli at days 5 and 10, this is paralleled by increasing 9. Wada T, Yokoyama H, Furuichi K, Kobayashi KI, Harada K,
TGF-b protein levels (Table 2). Moreover, this decrease Naruto M, Su SB, Akiyama M, Mukaida N, Matsushima K:
Intervention of crescentic glomerulonephritis by antibodies toin glomerular M/M cell number did not appear in the
monocyte chemotactic and activating factor (MCAF/MCP-1).nephritic animals that received anti–MCP-1 antiserum. FASEB J 10:1418–1425, 1996
In fact, in glomeruli of anti–MCP-1 antibody-treated ani- 10. Wenzel UO, Schneider A, Valente AJ, Abboud HE, Thaiss F,
Helmchen UM, Stahl RAK: Monocyte chemoattractant protein-1mals at day 10, more monocytes were detectable than in
mediates monocyte/macrophages influx in anti-thymocyte anti-untreated nephritic rats. These data make it very unlikely body-induced glomerulonephritis. Kidney Int 51:770–776, 1997
that the depletion of glomerular monocytes may account 11. Fujinaka H, Yamamoto T, Takeya M, Feng L, Kawasaki K,
Yaoita E, Kondo D, Wilson CB, Uchiyama M, Kihara I: Suppres-for the reduced TGF-b formation following MCP-1 anti-
sion of anti-glomerular basement membrane nephritis by adminis-serum. tration of anti-monocyte chemoattractant protein-1 antibody in
A beneficial effect of MCP-1 neutralization on glomer- WKY Rats. J Am Soc Nephrol 8:1174–1178, 1997
12. Pawluczyk IZA, Harris KPG: Macrophages promote proscleroticular and tubulointerstitial scarring of GN has recently
responses in cultured rat mesangial cells: A mechanism for thebeen demonstrated in other models of GN [9, 32]. Our
initiation of glomerulosclerosis. J Am Soc Nephrol 8:1525–1536,
data add more information about a possible pathogenetic 1997
13. Schneider A, Thaiss F, Rau HP, Wolf G, Zahner G, Helmchenmechanism of how renal scarring could be mediated by
U, Stahl RAK: Prostaglandin E1 inhibits collagen expression inMCP-1. In summary, our results delineate a new patho-
anti-thymocyte antibody induced glomerulonephritis: Possible role
genetic role of MCP-1 in the development of experimen- of TGF-b. Kidney Int 50:190–199, 1996
14. Stahl RAK, Thaiss F, Kahf S, Schoeppe W, Helmchen UM:tal GN.
Immune-mediated mesangial cell injury-biosynthesis and function
of prostanoids. Kidney Int 38:273–281, 1990
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